Pfizer to market Campto in the UK for advanced colorectal cancer

Published: 5-Oct-2004

Pfizer has successfully completed the acquisition of rights to all assets relating to Campto (irinotecan hydrochloride injection), a chemotherapy agent for treatment of advanced colorectal cancer, formerly held by Aventis, under the licence granted by Yakult Honsha Co., of Tokyo, Japan.


Pfizer has successfully completed the acquisition of rights to all assets relating to Campto (irinotecan hydrochloride injection), a chemotherapy agent for treatment of advanced colorectal cancer, formerly held by Aventis, under the licence granted by Yakult Honsha Co., of Tokyo, Japan.

Pfizer currently holds the rights to market Campto in the Americas and Australia under the brand name Camptosar. Through this acquisition, Pfizer now also has rights to market the product in Europe, Africa/Middle East and Asia, excluding Japan. The company will assume responsibility for all clinical studies of Campto initiated by Aventis now underway.

'This acquisition enhances our commitment to cancer research and better enables us to continue to explore the use of Campto alongside other treatments such as targeted therapies and in new therapeutic settings,' said Dr Bill Slichenmyer, vice president of oncology drug development.

  

You may also like